Literature DB >> 23213100

Results of annual screening in phase I of the United Kingdom familial ovarian cancer screening study highlight the need for strict adherence to screening schedule.

Adam N Rosenthal1, Lindsay Fraser, Ranjit Manchanda, Philip Badman, Susan Philpott, Jessica Mozersky, Richard Hadwin, Fay H Cafferty, Elizabeth Benjamin, Naveena Singh, D Gareth Evans, Diana M Eccles, Steven J Skates, James Mackay, Usha Menon, Ian J Jacobs.   

Abstract

PURPOSE: To establish the performance characteristics of annual transvaginal ultrasound and serum CA125 screening for women at high risk of ovarian/fallopian tube cancer (OC/FTC) and to investigate the impact of delayed screening interval and surgical intervention. PATIENTS AND METHODS: Between May 6, 2002, and January 5, 2008, 3,563 women at an estimated ≥ 10% lifetime risk of OC/FTC were recruited and screened by 37 centers in the United Kingdom. Participants were observed prospectively by centers, questionnaire, and national cancer registries.
RESULTS: Sensitivity for detection of incident OC/FTC at 1 year after last annual screen was 81.3% (95% CI, 54.3% to 96.0%) if occult cancers were classified as false negatives and 87.5% (95% CI, 61.7% to 98.5%) if they were classified as true positives. Positive and negative predictive values of incident screening were 25.5% (95% CI, 14.3 to 40.0) and 99.9% (95% CI, 99.8 to 100) respectively. Four (30.8%) of 13 incident screen-detected OC/FTCs were stage I or II. Compared with women screened in the year before diagnosis, those not screened in the year before diagnosis were more likely to have ≥ stage IIIc disease (85.7% v 26.1%; P = .009). Screening interval was delayed by a median of 88 days before detection of incident OC/FTC. Median interval from detection screen to surgical intervention was 79 days in prevalent and incident OC/FTC.
CONCLUSION: These results in the high-risk population highlight the need for strict adherence to screening schedule. Screening more frequently than annually with prompt surgical intervention seems to offer a better chance of early-stage detection.

Entities:  

Mesh:

Year:  2012        PMID: 23213100      PMCID: PMC3530690          DOI: 10.1200/JCO.2011.39.7638

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  39 in total

1.  Change in stage distribution observed with annual screening for ovarian cancer in BRCA carriers.

Authors:  R Manchanda; A Rosenthal; M Burnell; L Fraser; J Mackay; S Skates
Journal:  J Med Genet       Date:  2009-06       Impact factor: 6.318

2.  Prospectively detected cancer in familial breast/ovarian cancer screening.

Authors:  A Dørum; K Heimdal; K Løvslett; G Kristensen; L J Hansen; R Sandvei; A Schiefloe; B Hagen; A Himmelmann; F Jerve; K Shetelig; I Fjaerestad; C Tropé; P Møller
Journal:  Acta Obstet Gynecol Scand       Date:  1999-11       Impact factor: 3.636

3.  Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer.

Authors:  H A Risch; J R McLaughlin; D E Cole; B Rosen; L Bradley; E Kwan; E Jack; D J Vesprini; G Kuperstein; J L Abrahamson; I Fan; B Wong; S A Narod
Journal:  Am J Hum Genet       Date:  2001-02-15       Impact factor: 11.025

4.  MSH2 mutation carriers are at higher risk of cancer than MLH1 mutation carriers: a study of hereditary nonpolyposis colorectal cancer families.

Authors:  H F Vasen; A Stormorken; F H Menko; F M Nagengast; J H Kleibeuker; G Griffioen; B G Taal; P Moller; J T Wijnen
Journal:  J Clin Oncol       Date:  2001-10-15       Impact factor: 44.544

5.  Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: a report of 121 families with proven mutations.

Authors:  E Barrow; L Robinson; W Alduaij; A Shenton; T Clancy; F Lalloo; J Hill; D G Evans
Journal:  Clin Genet       Date:  2009-02       Impact factor: 4.438

6.  Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).

Authors:  Usha Menon; Aleksandra Gentry-Maharaj; Rachel Hallett; Andy Ryan; Matthew Burnell; Aarti Sharma; Sara Lewis; Susan Davies; Susan Philpott; Alberto Lopes; Keith Godfrey; David Oram; Jonathan Herod; Karin Williamson; Mourad W Seif; Ian Scott; Tim Mould; Robert Woolas; John Murdoch; Stephen Dobbs; Nazar N Amso; Simon Leeson; Derek Cruickshank; Alistair McGuire; Stuart Campbell; Lesley Fallowfield; Naveena Singh; Anne Dawnay; Steven J Skates; Mahesh Parmar; Ian Jacobs
Journal:  Lancet Oncol       Date:  2009-03-11       Impact factor: 41.316

7.  Screening for familial ovarian cancer: poor survival of BRCA1/2 related cancers.

Authors:  D G Evans; K N Gaarenstroom; D Stirling; A Shenton; L Maehle; A Dørum; M Steel; F Lalloo; J Apold; M E Porteous; H F A Vasen; C J van Asperen; P Moller
Journal:  J Med Genet       Date:  2008-04-15       Impact factor: 6.318

8.  Metabolic syndrome after risk-reducing salpingo-oophorectomy in women at high risk for hereditary breast ovarian cancer: a controlled observational study.

Authors:  Trond M Michelsen; Are H Pripp; Serena Tonstad; Claes G Tropé; Anne Dørum
Journal:  Eur J Cancer       Date:  2008-11-12       Impact factor: 9.162

9.  Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers.

Authors:  Timothy R Rebbeck; Noah D Kauff; Susan M Domchek
Journal:  J Natl Cancer Inst       Date:  2009-01-13       Impact factor: 13.506

10.  The preclinical natural history of serous ovarian cancer: defining the target for early detection.

Authors:  Patrick O Brown; Chana Palmer
Journal:  PLoS Med       Date:  2009-07-28       Impact factor: 11.069

View more
  39 in total

1.  Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk - Combined Results from Two Screening Trials.

Authors:  Steven J Skates; Mark H Greene; Saundra S Buys; Phuong L Mai; Powel Brown; Marion Piedmonte; Gustavo Rodriguez; John O Schorge; Mark Sherman; Mary B Daly; Thomas Rutherford; Wendy R Brewster; David M O'Malley; Edward Partridge; John Boggess; Charles W Drescher; Claudine Isaacs; Andrew Berchuck; Susan Domchek; Susan A Davidson; Robert Edwards; Steven A Elg; Katie Wakeley; Kelly-Anne Phillips; Deborah Armstrong; Ira Horowitz; Carol J Fabian; Joan Walker; Patrick M Sluss; William Welch; Lori Minasian; Nora K Horick; Carol H Kasten; Susan Nayfield; David Alberts; Dianne M Finkelstein; Karen H Lu
Journal:  Clin Cancer Res       Date:  2017-01-31       Impact factor: 12.531

Review 2.  Risk-Reducing Strategies for Ovarian Cancer in BRCA Mutation Carriers: A Balancing Act.

Authors:  Roi Tschernichovsky; Annekathryn Goodman
Journal:  Oncologist       Date:  2017-03-17

3.  Disparities in ovarian cancer survival in the United States (2001-2009): Findings from the CONCORD-2 study.

Authors:  Sherri L Stewart; Rhea Harewood; Melissa Matz; Sun Hee Rim; Susan A Sabatino; Kevin C Ward; Hannah K Weir
Journal:  Cancer       Date:  2017-12-15       Impact factor: 6.860

4.  Leveraging biospecimen resources for discovery or validation of markers for early cancer detection.

Authors:  Sheri D Schully; Danielle M Carrick; Leah E Mechanic; Sudhir Srivastava; Garnet L Anderson; John A Baron; Christine D Berg; Jennifer Cullen; Eleftherios P Diamandis; V Paul Doria-Rose; Katrina A B Goddard; Susan E Hankinson; Lawrence H Kushi; Eric B Larson; Lisa M McShane; Richard L Schilsky; Steven Shak; Steven J Skates; Nicole Urban; Barnett S Kramer; Muin J Khoury; David F Ransohoff
Journal:  J Natl Cancer Inst       Date:  2015-02-16       Impact factor: 13.506

5.  Selected medical interventions in women with a deleterious BRCA mutation: a population-based study in British Columbia.

Authors:  G E Hanley; J N McAlpine; R Cheifetz; K A Schrader; M McCullum; D Huntsman
Journal:  Curr Oncol       Date:  2019-02-01       Impact factor: 3.677

6.  Baseline and post prophylactic tubal-ovarian surgery CA125 levels in BRCA1 and BRCA2 mutation carriers.

Authors:  Ying Chen; Elizabeth Bancroft; Sue Ashley; Audrey Arden-Jones; Sarah Thomas; Susan Shanley; Sibel Saya; Emma Wakeling; Rosalind Eeles
Journal:  Fam Cancer       Date:  2014-06       Impact factor: 2.375

7.  Features of ovarian cancer in Lynch syndrome (Review).

Authors:  Kanako Nakamura; Kouji Banno; Megumi Yanokura; Miho Iida; Masataka Adachi; Kenta Masuda; Arisa Ueki; Yusuke Kobayashi; Hiroyuki Nomura; Akira Hirasawa; Eiichiro Tominaga; Daisuke Aoki
Journal:  Mol Clin Oncol       Date:  2014-08-20

8.  Use of CA125 and HE4 serum markers to predict ovarian cancer in elevated-risk women.

Authors:  Beth Y Karlan; Jason Thorpe; Kate Watabayashi; Charles W Drescher; Melanie Palomares; Mary B Daly; Pam Paley; Paula Hillard; M Robyn Andersen; Garnet Anderson; Ronny Drapkin; Nicole Urban
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-05-01       Impact factor: 4.254

9.  A multiplexable, microfluidic platform for the rapid quantitation of a biomarker panel for early ovarian cancer detection at the point-of-care.

Authors:  Basil H Shadfan; Archana R Simmons; Glennon W Simmons; Andy Ho; Jorge Wong; Karen H Lu; Robert C Bast; John T McDevitt
Journal:  Cancer Prev Res (Phila)       Date:  2014-11-11

Review 10.  Challenging and complex decisions in the management of the BRCA mutation carrier.

Authors:  Daniela L Stan; Lynne T Shuster; Myra J Wick; Casey L Swanson; Sandhya Pruthi; Jamie N Bakkum-Gamez
Journal:  J Womens Health (Larchmt)       Date:  2013-08-29       Impact factor: 2.681

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.